A Multicenter, phase I open-label dose escalation study of ABBV-085 an antibody drug conjugated in subjects with advanced solid tumors.
Clinical Trial Grant
Administered By
Duke Cancer Institute
Awarded By
AbbVie Inc.
Start Date
July 1, 2016
End Date
June 30, 2020
Administered By
Duke Cancer Institute
Awarded By
AbbVie Inc.
Start Date
July 1, 2016
End Date
June 30, 2020